Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.50 Average Price Target from Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) have received an average recommendation of "Buy" from the six research firms that are currently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $30.50.

Several research firms have issued reports on TYRA. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, January 13th. Wedbush reaffirmed an "outperform" rating and set a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. Bank of America upgraded shares of Tyra Biosciences from a "neutral" rating to a "buy" rating and upped their price objective for the company from $22.00 to $31.00 in a report on Friday, October 18th. Finally, UBS Group initiated coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They set a "buy" rating and a $28.00 target price for the company.

Tyra Biosciences Trading Down 1.4 %

Shares of Tyra Biosciences stock traded down $0.20 on Friday, reaching $13.65. 226,709 shares of the company were exchanged, compared to its average volume of 258,873. The company has a market capitalization of $690.73 million, a price-to-earnings ratio of -8.48 and a beta of 1.05. Tyra Biosciences has a one year low of $13.27 and a one year high of $29.60. The company has a 50-day moving average of $15.22 and a 200 day moving average of $18.88.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.01). Analysts predict that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Nina S. Kjellson sold 3,993 shares of Tyra Biosciences stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total value of $65,325.48. Following the completion of the sale, the director now directly owns 3,707,420 shares in the company, valued at approximately $60,653,391.20. The trade was a 0.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 16,597 shares of company stock worth $270,500 in the last quarter. 15.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tyra Biosciences

Large investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Tyra Biosciences during the 4th quarter valued at $149,000. Franklin Resources Inc. acquired a new position in Tyra Biosciences in the third quarter valued at about $278,000. Valence8 US LP bought a new stake in Tyra Biosciences during the third quarter worth about $310,000. SG Americas Securities LLC acquired a new stake in Tyra Biosciences during the third quarter worth about $311,000. Finally, The Manufacturers Life Insurance Company bought a new position in Tyra Biosciences in the 3rd quarter valued at about $333,000. Institutional investors and hedge funds own 84.14% of the company's stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.